Ellevest, Inc. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.

Quarter-by-quarter ownership
Ellevest, Inc. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$1,878
+87.8%
330.0%0.00%
Q3 2022$1,000
-66.7%
33
-56.0%
0.00%
Q2 2022$3,000
+50.0%
75
+21.0%
0.00%
Q1 2022$2,0000.0%620.0%0.00%
Q4 2021$2,000
-66.7%
62
-56.6%
0.00%
-100.0%
Q3 2021$6,000
-33.3%
143
-25.5%
0.00%0.0%
Q2 2021$9,0000.0%192
-14.7%
0.00%0.0%
Q1 2021$9,000
+28.6%
225
+36.4%
0.00%0.0%
Q4 2020$7,000
+250.0%
165
+111.5%
0.00%
Q3 2020$2,000
+100.0%
78
+105.3%
0.00%
Q2 2020$1,000
-50.0%
38
-58.7%
0.00%
-100.0%
Q1 2020$2,000
+100.0%
92
+17.9%
0.00%
Q4 2019$1,000780.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders